In the 9 years since its discovery, cancer‐testis antigen NY‐ESO‐1 has made one of the
fastest transitions from molecular, cellular, and immunological description to vaccine and …

Montanide ISA™ 51 (ISA 51) is a vaccine adjuvant which has been tested in therapeutic and
prophylactic vaccine trials. The aim of this review is to present a comprehensive examination …

The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of
outcome in patients with multiple myeloma (MM). Gene expression profiling (GEP) of such …

During the last decade, increased understanding of the molecular mechanisms responsible
for immune activation to protect against challenges by tumor cells has revolutionized the …

Synthetic peptide vaccines aiming at the induction of a protective CD8+ T-cell response
against infectious or malignant diseases are widely used in the clinic but, despite their …

The purpose of our present study is to identify a tumor-specific antigen capable of inducing a
specific cellular immune response in lung cancer patients. We established a lung …

Purpose: Human melanoma cells express shared antigens recognized by CD8+ T
lymphocytes, the most common of which are melanocytic differentiation proteins and cancer …

We recently showed that vaccination with a complex of cholesterol-bearing hydrophobized
pullulan and NY-ESO-1 protein (CHP-NY-ESO-1) elicited antibody responses in 9 of 9 …

purpose. To assess the expression of PD-L1 on human uveal melanomas and its potential to
suppress T-cell function. methods. A panel of primary and metastatic uveal melanoma cell …

Interest for cancer vaccination started more than 30 years ago after the demonstration that
both in animal models and later on in patients it is possible to generate anti-tumor immune …